John is a discovery biologist and an entrepreneur and brings 25 years of experience in pathological cellular mechanisms of neurodegeneration.  After his post-doc at Harvard Medical School, he initiated and co-lead Biogen’s therapeutic discovery program in amyotrophic lateral sclerosis (ALS) before joining the ALS Therapy Development Institute as Director of Discovery Biology.  John holds several patents for biologic based therapeutics and gene therapy methods directed towards neurodegenerative diseases.  John has many years experience with the production and preclinical disease model testing of AAV vectors and nucleic acid based therapeutics, including ASOs. When not tending to biology and small businesses John seeks calm practicing yoga, baking bread, and cultivating an urban garden with his wife.